Chelation vs statins for treating cardiovascular disease

EDTA chelation is one of the most effective, least expensive, and safest treatments for cardiovascular disease.

As you consider treatment options to support your patients, we highlight two important considerations:

  • can chelation reduce the risk of a major coronary event?
  • what are the Numbers Needed to Treat for chelation vs statins?

Clinical trial results

The 2013 TACT trial showed that Chelation Therapy can reduce cardiovascular events in patients with established cardiovascular disease, especially with concurrent diabetes. Only six patients with diabetes had to be treated with chelation to prevent one adverse outcome – less than half the Number Needed to Treat (NNT) with statins.

Relative risk reduction of major coronary event

Treatment All patients post-MI Patients post-MI with diabetes
 EDTA Chelation  18%  41%
 EDTA + OMVM *  26%  51%
 Statin/genfibrozil  22% **  21%

* OMVM = oral multivitamins and multiminerals.
** Based on non-diabetic patient = 23%. No data for all patients.

NNT to prevent a cardiovascular event in secondary prevention population

Treatment All patients Patients with diabetes
EDTA Chelation 18 6.5
EDTA + OMVM * 12 5.5
Statin 16 15

* OMVM = oral multivitamins and multiminerals.

References

  • Costa, J., Borges, M., et al. (2006). Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 332, 1115-1124.
  • Escolar E, Lamas GA, Mark DB, et al. (2014). The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes. 7:15–24.
  • Lamas GA, et al. (2013). Effect of Disodium EDTA Chelation Regimen on Cardiovascular Events in Patients with Previous Myocardial Infarction: the TACT Randomized Trial. The Journal of the American Medical Association 309, 1241-1250.